Abbott receives CE Mark for next-gen MitraClip

September 22, 2020  –  Abbott (Abbott Park, IL) received CE Mark for its fourth-generation MitraClip Transcatheter Mitral Valve Repair System. Known as MitraClip G4, the device is now approved for use in Europe and other countries that recognize CE Mark as a non-surgical option for the treatment of mitral regurgitation (MR), or a leaky heart valve. The device is already approved for use in the U.S.

The MitraClip G4 system provides physicians with enhancements to MitraClip’s clip-based technology, building upon the device’s proven delivery system. In addition to offering advanced steering during implantation, the new delivery system offers four clip sizes, including two wider clips, for doctors to have a greater variety of treatment options that can be tailored to a patients’ unique mitral valve anatomy.

The newest-generation device also offers independently controlled grippers, if needed, that allow physicians to grasp one or both mitral valve leaflets at a time during the MitraClip procedure.

Learn More